APA (7th ed.) Citation

YY, Z., AQ, L., F, Y., YX, D., YS, H., XJ, M., . . . M, F. (2026). Targeting BCL9/BCL9L enhances CD4+ T cell-mediated Th1 antitumor immunity through activation of STAT1/STAT4 signaling. Acta pharmacologica Sinica. https://doi.org/10.1038/s41401-026-01845-2

Chicago Style (17th ed.) Citation

YY, Zhu, et al. "Targeting BCL9/BCL9L Enhances CD4+ T Cell-mediated Th1 Antitumor Immunity Through Activation of STAT1/STAT4 Signaling." Acta Pharmacologica Sinica 2026. https://doi.org/10.1038/s41401-026-01845-2.

MLA (9th ed.) Citation

YY, Zhu, et al. "Targeting BCL9/BCL9L Enhances CD4+ T Cell-mediated Th1 Antitumor Immunity Through Activation of STAT1/STAT4 Signaling." Acta Pharmacologica Sinica, 2026, https://doi.org/10.1038/s41401-026-01845-2.